Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab vedotin)
Catalog No.
F1439
Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab vedotin)
Featured Products
Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) consisting of a humanizedAnti-NaPi2b Lifastuzumab vedotin is a monoclonal antibody and the antimitotic cytotoxic agent monomethyl auristatin E (MMAE). Lifastuzumab vedotin is used to treat platinum-resistant ovarian cancer.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
1401812-88-1
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
NAPI3B, RG-7599
100 mM Pro 20 mM Arg pH 5.0. No preservative!
O95436
Human
MMAE
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
The drug-to-antibody ratio (DAR) of the Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) is 3.7.
NaPi2b / SLC34A2
Please avoid freeze-thaw cycles.